Aurobindo Pharma has informed pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on Monday, February 9, 2026, to consider and approve, the Standalone & Consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2025. Further to its letter dated December 24, 2025 whereby the company has informed the closure of Trading Window of the Company from January 1, 2026 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2025, the company has informed that the Trading Window will remain closed up to February 11, 2026 and shall be re-opened on February 12, 2026.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: